Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMVG9YN)

Drug Name

Fencamfamine Drug Info

Synonyms

Euvitol; Fenacamfamin; Fencamfamin; Fencamfamina; Fencamfaminum; Fencanfamina; Reactivan; Fencamfamina [DCIT]; Fencamfamin (INN); Fencamfamin [INN:BAN]; Fencamfamine [INN-French]; Fencamfaminum [INN-Latin]; Fencanfamina [INN-Spanish]; Glucoenergan (TN); Reactivan (TN); N-ethyl-2-phenylbicyclo[2.2.1]heptan-3-amine; N-ethyl-3-phenylbicyclo(2.2.1)heptan-2-amine; 2-Ethylamino-3-phenylnorbornane; 2-Phenyl-3-ethylaminobicyclo(2.2.1)heptane; 2-ethylamino-3-phenylnorcamphane; 3-Phenyl-N-ethyl-2-norbornanamine

Indication

Disease Entry	ICD 11	Status	REF
Depressive fatigue	MG22	Withdrawn from market	[1]

Therapeutic Class

Central Nervous System Stimulants

Cross-matching ID

PubChem CID: 14584
ChEBI ID: CHEBI:134895
CAS Number: CAS 1209-98-9
TTD Drug ID: DMVG9YN

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Dopamine D2 receptor (D2R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[3]
Haloperidol	DM96SE0	Delirium		Approved	[4]
Perphenazine	DMA4MRX	Schizophrenia	6A20	Approved	[5]
Perazine	DM2AOTZ	Psychotic disorder	6A20-6A25	Approved	[6]
Domperidone	DMBDPY0	Gastrointestinal disease	DE2Z	Approved	[7]
Levodopa	DMN3E57	Parkinson disease	8A00.0	Approved	[8]
Quetiapine	DM1N62C	Anorexia nervosa cachexia	6B80	Approved	[9]
Pimozide	DMW83TP	Schizophrenia	6A20	Approved	[10]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[11]
Iloperidone	DM6AUFY	Schizophrenia	6A20	Approved	[12]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine D2 receptor (D2R)	TTEX248	DRD2_HUMAN	Agonist	[2]

------------------------------------------------------------------------------------

References

1	Drug information of Fencamfamine, 2008. eduDrugs.
2	Dopamine uptake inhibiting versus dopamine releasing properties of fencamfamine: an in vitro study. Biochem Pharmacol. 1983 Aug 1;32(15):2329-31.
3	The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
4	Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
5	CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
6	Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87.
7	Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
8	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
9	Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
10	[The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1.
11	Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
12	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.